A niche pre-clinial contract research organisation and Edinburgh BioQuarter tenant, Aquila was originally set up in 2011 by academics the form the University of Edinburgh.
The Aquila team has more than doubled in size in the last year. While it is currently 14 members strong, it plans to increase that number by over 50% to 22 by 2017. The expansion ensures that the organisation will be prepared for any increases in the demand for its early-stage immuno-oncology and histology services.
The RSA funding has allowed Aquila to expand its recruitment plans and invest in its people and technical capabilities. The additional resources mean they can now offer assays using an IncuCyte Zoom, allowing its team to deliver insights into cellular processes, such as ‘T cell killing of tumors’ via real-time quantitative live-cell analysis.
Want to work in one of the largest life sciences clusters in Europe? From hands-on scientists and technologists to researchers to CEOs, there are exciting opportunities at every level.
Come join us.